Related references
Note: Only part of the references are listed.HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With Schizophrenia A Replication Study
Hans Mulder et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2009)
The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment Curacao extrapyramidal syndromes study IX
B. Wilffert et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment
Meenal Gupta et al.
PHARMACOGENOMICS (2009)
Olanzapine-induced weight gain is associated with the-759C/T and-697G/C polymorphisms of the HTR2C gene
B. R. Godlewska et al.
PHARMACOGENOMICS JOURNAL (2009)
The role of RNA editing of the serotonin 2C receptor in a rat model of oro-facial neuropathic pain
Aya Nakae et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2008)
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting
Malin Alenius et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2008)
Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia
Masashi Ikeda et al.
PHARMACOGENOMICS (2008)
The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients
Martina Rojnic Kuzman et al.
PSYCHIATRY RESEARCH (2008)
Effects of the dopamine D-3 receptor (DRD3) gene polymorphisms on risperidone response: A pharmacogenetic study
Jiekun Xuan et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia
Lei Wang et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2007)
The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia
Hans Mulder et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
M. J. Arranz et al.
MOLECULAR PSYCHIATRY (2007)
5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity
Matthew J. Hill et al.
BRAIN RESEARCH (2007)
Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in Neuro-2A Cells - an involvement of protein kinases
A Basta-Kaim et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Complex HTR2C linkage disequilibrium and promoter associations with body mass index and serum leptin
S McCarthy et al.
HUMAN GENETICS (2005)
Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs
Y Shi et al.
CELL RESEARCH (2005)
Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response
GP Reynolds et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain
PR Buckland et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Haploview: analysis and visualization of LD and haplotype maps
JC Barrett et al.
BIOINFORMATICS (2005)
Optimal dosing with risperidone: Updated recommendations
R Williams
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Genetic variants of the serotonin system and weight change during clozapine treatment
CJ Hong et al.
PHARMACOGENETICS (2001)
Pharmacogenetics and the serotonin system: initial studies and future directions
J Veenstra-VanderWeele et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia:: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility
RH Segman et al.
PSYCHOPHARMACOLOGY (2000)
Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and Type II diabetes
X Yuan et al.
DIABETOLOGIA (2000)
Share Paper
